TABLE 2.

Clinical evaluation of ezetimibe on cancer risk.

Trial	Patients	Follow-up	Treatment arms	Main results	References
SEAS	1873	4.0-year	ezetimibe 10 mg + Simvastatin 40 mg	ezetimibe/simvastatin seemed to increase cancer risk	Rossebø et al., (2008)
SHARP	9,264	2.7-year (mean)	ezetimibe 10 mg + Simvastatin 20 mg	there was no association between ezetimibe/simvastatin and the increased cancer risk	Peto et al., (2008)
IMPROVE-IT	11,353	1.0-year (mean)	ezetimibe 10 mg + Simvastatin 40 mg		Peto et al., (2008)
Anders et al	1,359	21-month	ezetimibe 10 mg + Simvastatin 40 mg	ezetimibe/simvastatin did not increased cancer risk	Green et al., (2014)
Robert P et al	17,708	6.0-year (mean)	Simvastatin 40 mg alone or ezetimibe 10 mg + Simvastatin 40 mg	ezetimibe/simvastatin had no effect on cancer risk	Giugliano et al., (2020)